Curis (CRIS) Reports Submission of MAA for Vismodegib to EMA

Curis, Inc. (Nasdaq: CRIS), announced that its collaborator Roche has submitted a Marketing Authorization Application (MAA) for vismodegib (GDC-0449, RG3616) to the European Medicines Agency (EMA). The MAA is currently under review for the treatment of adults with advanced basal cell carcinoma (BCC) for whom surgery is considered inappropriate. Vismodegib is a first-in-class, investigational, oral medicine designed to selectively inhibit signaling in the Hedgehog pathway and is being developed by Roche and Genentech, under a collaboration agreement between Curis and Genentech, a member of the Roche Group (OTCBB: RHHBY).

Curis earned a $6 million milestone payment from Genentech as a result of the MAA submission to the EMA. If vismodegib receives Marketing Authorization by the EMA , Curis will also be entitled to receive an additional milestone payment as well as royalties on any future sales.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Alnylam partners with Inceptive in $2B AI collaboration for drug discovery
• Iovance receives Australia approval for melanoma therapy Amtagvi
• QXO prices $3 billion in senior notes to fund TopBuild acquisition